Sichuan Baili Pharmaceutical Co., Ltd.

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2023-11-02
Last Posted Date
2024-07-18
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Target Recruit Count
58
Registration Number
NCT06114511
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2023-10-04
Last Posted Date
2024-07-18
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Target Recruit Count
40
Registration Number
NCT06066203
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2023-09-21
Last Posted Date
2024-07-18
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Target Recruit Count
58
Registration Number
NCT06042894
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors

First Posted Date
2023-09-11
Last Posted Date
2024-07-18
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Target Recruit Count
42
Registration Number
NCT06031584
Locations
🇨🇳

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

First Posted Date
2023-08-23
Last Posted Date
2024-10-21
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Target Recruit Count
186
Registration Number
NCT06006169
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2023-08-14
Last Posted Date
2024-10-24
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Target Recruit Count
130
Registration Number
NCT05990803
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2023-07-28
Last Posted Date
2024-07-18
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Target Recruit Count
52
Registration Number
NCT05965856
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

First Posted Date
2023-07-21
Last Posted Date
2024-07-18
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Target Recruit Count
121
Registration Number
NCT05956587
Locations
🇨🇳

Chongqing University Cancer Hospital, Chongqing, Chongqing, China

🇨🇳

Fujian Cancer Hospital, Fuzhou, Fujian, China

🇨🇳

Liuzhou People's Hospital, Liuzhou, Guangxi, China

and more 13 locations

A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2023-07-18
Last Posted Date
2024-07-18
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Target Recruit Count
160
Registration Number
NCT05949606
Locations
🇨🇳

Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath